Efaproxiral
Overview[edit | edit source]
Efaproxiral is a synthetic small molecule that acts as an allosteric modifier of hemoglobin. It is primarily investigated for its potential to enhance the delivery of oxygen to tissues by decreasing the oxygen affinity of hemoglobin, thereby facilitating the release of oxygen to hypoxic tissues.
Mechanism of Action[edit | edit source]
Efaproxiral works by binding to the hemoglobin molecule and stabilizing the deoxygenated form of hemoglobin, which reduces its affinity for oxygen. This shift in the oxygen-hemoglobin dissociation curve allows for more efficient release of oxygen to tissues, particularly under conditions of hypoxia.
Clinical Applications[edit | edit source]
Efaproxiral has been studied in the context of cancer treatment, particularly in conjunction with radiation therapy. The rationale is that by increasing oxygen delivery to tumors, efaproxiral can enhance the effectiveness of radiation therapy, as oxygen is a potent radiosensitizer.
Pharmacokinetics[edit | edit source]
Efaproxiral is administered intravenously and has a relatively short half-life. It is rapidly distributed throughout the body and is primarily excreted via the renal route. The pharmacokinetic profile of efaproxiral necessitates careful dosing to achieve the desired therapeutic effect without causing excessive oxygen release in non-target tissues.
Safety and Side Effects[edit | edit source]
The use of efaproxiral is associated with several potential side effects, including headache, dizziness, and nausea. More serious adverse effects can include hypotension and tachycardia, which require careful monitoring during administration.
Research and Development[edit | edit source]
Research into efaproxiral has focused on its potential to improve outcomes in oncology, particularly in brain tumors and other solid tumors where hypoxia is a limiting factor in treatment efficacy. However, clinical trials have yielded mixed results, and further studies are needed to fully understand its role in cancer therapy.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
